Cynosure Lutronic has won Health Canada clearance of XERF, a radio frequency (RF)-enabled skin tightening treatment device. XERF tightens skin without the need for numbing, needles, or downtime, and is safe for all skin types.

“The clearance of XERF in Canada marks an exciting milestone for Cynosure Lutronic as we expand our presence in North America,” Cynosure Lutronic North America President Lowinn Kibbey said. “As patients continue to seek effective treatments to tighten and revitalize their skin, they often face challenges with discomfort or downtime. With XERF, we offer a solution that delivers exceptional results while providing a more comfortable experience. This allows both patients and providers to achieve their desired outcomes with greater ease and confidence.”

XERF’s Key Features

• World’s first single shot, multi-frequency monopolar RF technology: This innovation combines 6.78 MHz and 2 MHz frequencies, enabling providers to precisely deliver energy at multiple tissue depths, effectively heating the fibrous septae to generate both immediate and lasting skin tightening results.
• Wave Fit pulse and Advanced Integrated Cryogen Delivery (ICD) Cooling technology: These advanced technologies work in tandem to regulate energy delivery and maintain optimal surface temperature, ensuring a comfortable treatment without the need for numbing.
• Innovative spider pattern tip: Designed to reduce skin edge effects, this tip ensures a controlled treatment environment, increasing treatment efficacy and patient safety.

“As a fellowship-trained cosmetic dermatologist, we prioritize treatments in our clinic that can consistently deliver results with minimal risk and downtime. XERF incorporates the newest technology to safely deliver energy deep into the skin, while offering intelligent cooling for superior protection and patient comfort,” stated Jordan V. Wang, M.D.,* medical director at Laser & Skin Surgery Center of Pennsylvania and medical research director at Roy Geronemus, M.D.’s office.

XERF made its market debut las year and is currently sold in Korea, Japan, and Hong Kong. With its Health Canada clearance, Cynosure Lutronic is prioritizing Canada as its first North American launch market.

With more than 30 years of combined innovation and action in energy-based devices and medical aesthetic treatments, Cynosure Lutronic enables dermatologists, plastic surgeons, medical spas, and other healthcare practitioners to deliver non-invasive and minimally invasive procedures to their patients. Committed to R&D at the forefront of aesthetic technology, Cynosure Lutronic offers an extensive aesthetic device portfolio, providing its customers with a comprehensive range of solutions for skin resurfacing and revitalization, hair removal, vascular lesion treatment, skin toning, and body contouring. Cynosure Lutronic sells its products globally through a direct sales force in the United States, Canada, France, Morocco, Germany, Spain, the United Kingdom, Australia, China, Japan, and Korea, and through international distributors in approximately 130 other countries.

Hahn & Co. is Korea’s largest private equity investment firm operating in Korea. Companies controlled by Hahn & Co. generate revenues over KRW20 trillion ($15 billion) with assets of KRW34 trillion ($27 billion) and more than 30,000 employees worldwide (www.hcompany.com).

XERF is indicated for use in dermatological procedures requiring the coagulation of soft tissue.

* Dr. Jordan Wang is a paid consultant of Cynosure Lutronic.